The shareholders have been actively engaged in XNK Therapeutics since the start in 2012, each contributing with their unique competence as well as investing their own money. Despite limited equity investments, the company has taken its leading investigational drug candidate, CellProtect, to Phase II. To accelerate the development of CellProtect, XNK Therapeutics has decided to launch a financing round in XNK Therapeutics.

For more information please contact CEO Johan Liwing (